Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Rapamycin in fibrotic diseases: beneficial or detrimental agent?

Xu XF, Dai HP.

Chin Med J (Engl). 2013 Apr;126(7):1364-9. No abstract available.

PMID:
23557573
2.

Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.

Yoshizaki A, Yanaba K, Yoshizaki A, Iwata Y, Komura K, Ogawa F, Takenaka M, Shimizu K, Asano Y, Hasegawa M, Fujimoto M, Sato S.

Arthritis Rheum. 2010 Aug;62(8):2476-87. doi: 10.1002/art.27498.

3.

Effects of delayed rapamycin treatment on renal fibrosis and inflammation in experimental ischemia reperfusion injury.

Liu M, Agreda P, Crow M, Racusen L, Rabb H.

Transplant Proc. 2009 Dec;41(10):4065-71. doi: 10.1016/j.transproceed.2009.08.083.

PMID:
20005342
4.

[Successful treatment of a severe case of idiopathic pulmonary fibrosis with rapamycin].

Buschhausen L, Kamm M, Arns W, Schulze-Lohoff E, Weber M.

Med Klin (Munich). 2005 Mar 15;100(3):161-4. German.

PMID:
15966446
5.

[Rapamycin: a new immunosuppressive agent capable of inhibiting chronic rejection?].

Viklický O, Matl I.

Cas Lek Cesk. 2001 Jan 19;140(1):22-5. Czech.

PMID:
11242980
6.

Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy.

Bonegio RG, Fuhro R, Wang Z, Valeri CR, Andry C, Salant DJ, Lieberthal W.

J Am Soc Nephrol. 2005 Jul;16(7):2063-72. Epub 2005 May 25.

7.

Efficacy of rapamycin in scleroderma: a case study.

Fried L, Kirsner RS, Bhandarkar S, Arbiser JL.

Lymphat Res Biol. 2008;6(3-4):217-9. doi: 10.1089/lrb.2008.1006.

8.

Considerations in sirolimus use in the early and late post-transplant periods.

Patel SJ, Elliott EN, Knight RJ, Gaber LW, Gaber AO.

Expert Opin Drug Saf. 2009 Jul;8(4):421-34. doi: 10.1517/14740330903037156. Review.

PMID:
19522662
9.

Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis.

Nadiminti U, Arbiser JL.

J Am Acad Dermatol. 2005 Feb;52(2 Suppl 1):17-9.

PMID:
15692505
10.

Sirolimus: its discovery, biological properties, and mechanism of action.

Sehgal SN.

Transplant Proc. 2003 May;35(3 Suppl):7S-14S. Review.

PMID:
12742462
11.

Sirolimus and its analogs and its effects on vascular diseases.

Adelman SJ.

Curr Pharm Des. 2010;16(36):4002-11. Review.

PMID:
21208186
12.

Rapamycin: a new string to the antiproteinuric bow?

Brunskill NJ.

J Am Soc Nephrol. 2005 Jul;16(7):1878-9. Epub 2005 Jun 8. No abstract available.

13.

Rapamycin on trial.

Sacks SH.

Nephrol Dial Transplant. 1999 Sep;14(9):2087-9. Review. No abstract available.

PMID:
10489213
14.

Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage?

Torras J, Herrero-Fresneda I, Gulias O, Flaquer M, Vidal A, Cruzado JM, Lloberas N, Franquesa Ml, Grinyó JM.

Nephrol Dial Transplant. 2009 Dec;24(12):3632-40. doi: 10.1093/ndt/gfp367. Epub 2009 Aug 11.

PMID:
19671594
15.

Rapamycin: clinical results and future opportunities.

Kahan BD, Camardo JS.

Transplantation. 2001 Oct 15;72(7):1181-93. Review. No abstract available.

PMID:
11602840
16.

The treatment of multifocal choroiditis associated choroidal neovascularization with sirolimus (rapamycin).

Nussenblatt RB, Coleman H, Jirawuthiworavong G, Davuluri G, Potapova N, Dahr SS, Ragheb JA, Levy-Clarke G.

Acta Ophthalmol Scand. 2007 Mar;85(2):230-1. No abstract available.

17.

Rapamycin slows heart transplant vasculopathy.

SoRelle R.

Circulation. 2003 Jul 8;108(1):e9001. No abstract available.

18.

Intrabiliary rapamycin may slow progression of primary sclerosing cholangitis.

Karaahmet F, Kılıncalp S, Altınbas A, Coban S, Yuksel O.

Aliment Pharmacol Ther. 2012 Feb;35(4):490-1. doi: 10.1111/j.1365-2036.2011.04974.x. No abstract available.

19.

Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent.

Cotterell AH, Fisher RA, King AL, Gehr TW, Dawson S, Sterling RK, Stravitz RT, Luketic VA, Sanyal AJ, Shiffman ML, Posner MP.

Clin Transplant. 2002;16 Suppl 7:49-51.

PMID:
12372044
20.

A novel immunosuppressive agent, sirolimus, in the treatment of Kaposi's sarcoma in a renal transplant recipient.

Yilmaz R, Akoglu H, Kirkpantur A, Kilickap S, Arici M, Altun B, Aki T, Erdem Y, Yasavul U, Turgan C.

Ren Fail. 2007;29(1):103-5.

PMID:
17365918

Supplemental Content

Support Center